Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-04-28

Butterfly Network, Inc.

Butterfly Network sells handheld whole-body ultrasound devices plus cloud workflow, education, AI, and partner-development tools for clinicians, health systems, and OEM partners.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Handheld ultrasound needs platform proof

The company has a credible path to outgrow normal medtech if it converts device adoption into sticky workflow and partner revenue. The key question is no longer product validity, but whether the newer revenue layers become repeatable enough to justify a premium.

Analysis

Thesis

Butterfly can grow from a handheld ultrasound device maker into a regulated imaging workflow and licensing platform, but the stock only works well if Embedded, enterprise software, and decentralized-care revenue become repeatable rather than episodic.

Last Economy Alignment

AI lowers training and workflow friction, which expands handheld ultrasound demand, while Butterfly still controls scarce hardware, trust, and integrations that are harder to commoditize than app-level AI.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.7x (from 5 most recent analyses)

Reasoning

I underwrite strong revenue compounding from core probe growth, better enterprise software attach, and a real but still bounded contribution from Embedded and home-based care. The stock can still work, but current valuation already prices some optionality, so most upside must come from proving revenue quality and mix shift, not a fantasy multiple.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The core risk is not whether Butterfly’s product works; it is whether management can turn a differentiated probe into a durable workflow and licensing business before larger incumbents compress pricing or bundle the category away. Regulatory timing, supplier concentration, and a still-premium valuation make 2026-2027 execution especially important.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

April 27, 2026 proxy materials set the annual meeting for June 18, 2026; governance update, not a thesis change.
As of April 28, 2026, the stock had pulled back from the prior week's highs, which trims near-term exuberance ahead of earnings.
No new home-care contract or FedRAMP announcement has surfaced yet; April 30, 2026 Q1 results remain the first hard operating check.

Forecast update

The core setup is intact, but after the rerating and before Q1 proof, I underwrite less value from narrative re-rating and more from operating delivery.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.42

They control the probe, the software, and the compliance-heavy workflow around it, so cheaper AI can make their product easier to use and more widely adopted. The risk is that bigger imaging companies copy the software layer and bundle the category before Butterfly deepens its grip on enterprise workflows.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$5.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research